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Abstract
Objectives. RA patients often present with low muscle mass and decreased strength. Quantitative MRI offers a
non-invasive measurement of muscle status. This study assessed whether MRI-based measurements of T2, fat
fraction, diffusion tensor imaging and muscle volume can detect differences between the thigh muscles of RA
patients and healthy controls, and assessed the muscle phenotype of different disease stages.
Methods. Thirty-nine RA patients (13 ‘new RA’—newly diagnosed, treatment naı̈ve, 13 ‘active RA’—persistent
DAS28 >3.2 for >1 year, 13 ‘remission RA’—persistent DAS28 <2.6 for >1 year) and 13 age and gender directly
matched healthy controls had an MRI scan of their dominant thigh. All participants had knee extension and flexion
torque and grip strength measured.
Results. MRI T2 and fat fraction were higher in the three groups of RA patients compared with healthy controls in
the thigh muscles. There were no clinically meaningful differences in the mean diffusivity. The muscle volume,
handgrip strength, knee extension and flexion were lower in all three groups of RA patients compared with healthy
controls.
Conclusion. Quantitative MRI and muscle strength measurements can potentially detect differences within the
muscles between RA patients and healthy controls. These differences may be seen in RA patients who are yet to
start treatment, those with persistent active disease, and those who were in clinical remission. This suggests that
the muscles in RA patients are affected in the early stages of the disease and that signs of muscle pathology and
muscle weakness are still observed in clinical remission.
Key words: muscle, rheumatoid arthritis, T2, body composition, MRI, strength
Introduction
RA is a chronic, progressive, autoimmune, inflammatory
disease with a prevalence of 0.8% in the UK [1]. The
aim is to diagnose and treat at the earliest opportunity
in order to to achieve clinical remission. Remission is
associated with improved function and reduced radio-
graphic progression. As well as joint damage, RA is also
associated with altered body composition [2]. This could
be due to an inactive lifestyle as a result of the disease,
drug-induced myopathies [3, 4] and the activation of the
nuclear factor kappa-beta pathway, which triggers
metabolic alterations leading to the degradation of
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. RA is associated with altered body composition, which can result in rheumatoid cachexia.
. Muscle deteriorates in early disease in RA as assessed by quantitative MRI.
. Signs of muscle pathology and weakness are still observed in rheumatoid patients in clinical remission.
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muscle tissue [5]. Furthermore, the production of TNF-a
and other inflammatory cytokines that are critical to the
pathogenesis of RA are reported to have catabolic
effects on skeletal muscle [6]. These combined factors
can result in rheumatoid cachexia (RC) [7–10]. RC is
characterized by the loss of muscle mass (muscle atro-
phy), changes in muscle fibre, increased inflammatory
biomarkers in the muscle and decreased strength, with
the preservation, or increase, of fat mass [8]. The preva-
lence of RC is not known as there is no consensus on
its definition and assessment. However, 40% of
patients with active disease suffer from RC [11], making
it one of the most common complications of RA. RC
has been shown to be associated with increased dis-
ease severity, reduced quality of life, increased fatigue
and increased morbidity and mortality, and can acceler-
ate age-related sarcopenia [9, 12–14]. Therefore, muscle
health is an important aspect of RA that should be con-
sidered. It is currently unknown at what stage muscle in-
volvement begins in RA patients, and whether the
muscle damage that is caused by the disease is
reversed when patients achieve disease remission.
The literature explaining the benefits of exercise in
patients with RA has grown in recent years. Evidence
suggests exercise has anti-inflammatory effects due to
the breakdown of fat, increasing the regulatory proper-
ties of the immune system and decreasing systemic
markers of inflammation, such as ESR [15, 16].
It has been demonstrated that aerobic and muscle
strengthening exercise increases physical function and
decreases pain, fatigue, disease activity and disability
[15, 17–20]. Therefore, it has been proposed that exer-
cise should be included in the routine management of
RA [21–24]. However, the amount of exercise performed
among patients with RA is lower than the level recom-
mended by international guidelines [25, 26]. This
reduced level of physical activity among RA patients is
often due to the misconception that exercise may further
damage the joints [18, 27–29].
Imaging techniques such as quantitative MRI can
measure non-invasively the biomarkers associated with
RC, such as inflammation (oedema), fatty infiltration
(myosteatosis), alterations in muscle fibres and muscle
atrophy, and may be able to provide further information
regarding muscle health in RA patients. This could im-
prove understanding of muscle involvement in RA and
aid in the development of preventative and therapeutic
strategies, such as exercise, medication and
supplements.
Quantitative T2 measurements in MRI can be meas-
ured using a spin echo MRI pulse-sequence with mul-
tiple echo times. MRI T2 measurements are sensitive to
fluid, which can be related to physiological or patho-
logical changes at the macromolecular level [30]. This is
regarded as an indirect measure of inflammation and
may have a role in the identification of muscle inflamma-
tion and oedema [31]. MR-based muscle fat fraction
measurements can be made by exploiting the fact that
water and fat have different resonance frequencies.
They provide a measurement for the proportion of fat in
a given voxel and are useful for identifying myosteatosis
in the muscle [32]. Diffusion tensor imaging techniques
can characterize the degree and direction of water diffu-
sion in the muscle. Diffusion is restricted to a different
degree in different fibres, therefore diffusion tensor
imaging is sensitive to changes in muscle microstruc-
ture. All three measurements have excellent repeatability
[33].
The aim of this study was to obtain preliminary data
comparing quantitative MRI measurements between RA
patients who were newly diagnosed, or with persistent
active disease, and in clinical remission with healthy
controls. The purpose was to estimate the extent to
which muscle state may differ from health in these dif-
ferent stages of RA progression.
Methods
Study design
This study was a cross-sectional pilot study conducted
at the Leeds Teaching Hospitals NHS Trust (LTHT).
Recruitment began in May 2017 and ended in
December 2018. Participants were recruited into the
Magnetic resonance imaging and UltraSound CLinical
Evaluation of muscle pathology (MUSCLE) study, which
was approved by the local research ethics committee
(17/EM/0079), and all participants provided written
informed consent. Fifty-two participants were recruited
into four separate groups of 13 participants each: Group
1—new RA, treatment naı̈ve; Group 2—RA with persist-
ent active disease for at least 1 year; Group 3—RA in
sustained remission for at least 1 year; and Group 4—
healthy controls.
RA groups were age and gender matched. Healthy
controls were recruited to match the RA patients. The
sample size was chosen based on guidelines of be-
tween 12 and 30 participants per group for pilot studies
[34, 35]. RA patients were recruited from clinics at
Chapel Allerton Hospital. Clinical parameters collected
included: BMI, 28-jont DAS (DAS28), early morning stiff-
ness, medication, disease duration, patient global as-
sessment of disease activity visual analogue scale and
inflammatory markers. RA patients had an established
diagnosis of RA based on the 2010 ACR/EULAR classifi-
cation criteria [36]. Patients were classified as (1) ‘new
RA’ if they were newly diagnosed with RA and had not
previously taken DMARDs or steroids. Patients were
classed as (2) ‘active RA’ if they had a diagnosis of RA
for >1 year, had DAS28 >3.2 at the time of recruitment
and had at least two of the following markers of active
disease within the past 12 months: (2.1) raised inflamma-
tory markers; (2.2) requiring steroid therapy; (2.3) DAS
>3.2 at a second time point within 12 months; (2.4) es-
calation to or recent changes in biologic medication.
Patients were classed as (3) ‘remission RA’ patients if
they had had a diagnosis of RA for >1 year and were in
clinical remission for the past 12 months determined by
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clinical opinion and a DAS28 <2.6 at the time of recruit-
ment and without a DAS28 >2.6 in the past 12 months.
Healthy participants were recruited from e-mail and
posters advertisements around the hospital. Inclusion
criteria for healthy controls were: (i) being asymptomatic
of muscle disease; (ii) no previous history of musculo-
skeletal or rheumatic disorders; (iii) not currently taking
or previously taken CS treatment within the past 3 years
with doses >5 mg/day; (iv) not currently taking or previ-
ously taken HMG-CoA reductase inhibitors for the past
3 years. These criteria were ascertained by self-report or
patient health record. Exclusion criteria for participants
were age <18 years, contraindications to MRI, previous
history of muscle disorder, spinal disease or neuropathy.
Magnetic resonance imaging measurements
MR data were acquired using a MAGNETOM Verio 3 T
MR scanner (Siemens Healthcare, Erlangen, Germany).
Two small four-channel flex coils were wrapped around
the dominant thigh and placed with the distal end of
both coils positioned 4 cm from the superior edge of the
patella. Participants advised what their dominant leg
was. If the participant was uncertain, the right leg was
chosen by default. Fat fraction, T2, mean diffusivity and
fractional anisotropy were measured in the hamstrings
and quadriceps.
As previously published [33], fat quantitation was per-
formed using a 40-slice, volume-interpolated breath-
hold examination (VIBE), 2-point Dixon sequence. T2, fat
fraction and diffusion measurements used one slice
(slice 20) and muscle volume measurements used the
30 central slices. Two-point VIBE Dixon was selected
because of its wide availability and well documented re-
cent use in the muscle [37–43]. Diffusion-weighted
images were acquired using a STimulated Echo
Aquisition Mode (STEAM) prototype sequence with an
echo-planar imaging readout [44] with SPAIR (spectral
adiabatic inversion recovery) fat suppression [33].
For T2 measurements axial images were obtained
using a T2-weighted, multi-echo, spin-echo sequence
with SPAIR fat suppression with an echo train length 16,
and echo times of 9.6, 19.2, 28.8, 38.4, 48.0, 57.6, 67.2,
76.8, 86.4, 96.0, 105.6, 115.2, 124.8, 134.4, 144.0 and
153.6 ms, repetition time of 1500 ms, slice thickness
5 mm, matrix 256 256, number of averages¼ 1, with a
field of view of 300300mm. To calculate T2 values the
signal intensity vs echo time decay curves from each re-
gion of interest were fitted with a mono-exponential
function. To reduce the effect of additional signal from
stimulated echoes the signal from the earliest time point
was excluded from the fit [45].
Muscle volume estimates were obtained using a semi-
automated algorithm that used fat fraction maps gener-
ated from the VIBE Dixon volume. The algorithm defined
a muscle voxel as any voxel within the thigh with a fat
fraction of <50%, excluding bone. To exclude muscle
from the contralateral leg, a bounding box was automat-
ically defined around the imaged leg using a threshold
derived from a histogram of the image signal intensities.
To exclude bone from the image, a seed point was
manually placed within the bone on the central slice of
the VIBE Dixon volume. A 3D connected components al-
gorithm (bwconncomp, MATLAB, Mathworks, Nattick,
MA, USA) was then used to grow a region within the ex-
tent of the bone. The in-phase Dixon image was used
for this step because of the excellent contrast between
the bright bone marrow and the dark, surrounding cor-
tical bone. Finally, a mask defining the muscle was
obtained by thresholding, with a fat fraction threshold of
50%, excluding voxels within bone, surrounding air and
contralateral leg. The threshold of <50% fat fraction
was chosen as it has been previously used in muscle
volume measurements in the lumbar multifidus [46, 47]
and erector spinae muscles [48, 49], and no previously
used threshold values have been used in the muscles of
the thigh. Muscle masks were only defined between
slice 5–35 of the 40-slice volume to avoid errors due to
signal drop-off at the outer extremities of the receive
coil. The volume was defined as the number of voxels in
the muscle mask multiplied by the voxel size, multiplied
by the slice width.
Muscle strength assessments
Knee extension and flexion isokinetic assessment of the
dominant thigh were performed following MRI examin-
ation at a controlled room temperature of 20C using an
isokinetic biodex system 4-muscle testing and rehabili-
tation isokinetic dynamometer (IPRS Mediquipe Ltd,
Little Blakenham, Suffolk, UK). Participants were
instructed to refrain from strenuous physical activity for
24 h prior to the examination. After a standardized
warm-up, participants were positioned on the equipment
according to the manufacturer’s instructions.
Gravitational correction was performed at 180.
Isokinetic knee extension-flexion (concentric-concentric)
at 60/s was used to collect data. Participants per-
formed three maximum effort repetitions for three sets,
separated by a 30 s rest interval. Measurements were
recorded between 0 and 135 as determined by manu-
facturer guidelines. Standardized verbal stimuli were
provided throughout the evaluation. Strength (Nm) was
the assessed variable. Alongside knee flexion and ex-
tension, handgrip strength (kg) was measured using a
Jamar plus isokinetic dynamometer (Patterson Medical,
Cedarburg, Wisconsin). Participants had their grip
strength measured in their right hand for three sets and
the mean measurement was taken.
Statistical analyses
Offline image analysis was performed using MATLAB
software (R2018b, Mathworks, Nattick, MA, USA).
Statistical analyses were performed using SPSS (IBM
SPSS Statistics for Windows, Version 25.0, IBM Corp.,
Armonk, NY, USA). One-way analysis of variance with
Dunnett’s post hoc analysis was used to test for signifi-
cant differences in quantitative MR and muscle strength
measurements between the disease stages. Spearman’s
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rank correlation was used to measure correlation. We
utilized rs-values 0.7 as indicative of a strong correl-
ation and rs  0.4 as indicative of a weak correlation
[50]. Although P-values have been presented as a guide-
line, primary emphasis has been placed on descriptive
data throughout.
Results
There were 75 patients recruited into the MUSCLE study
who had RA. No patients declined to take part. The
patients were categorized into the three groups of RA.
There were 27 newly diagnosed RA, 13 with active dis-
ease and 35 patients in clinical remission. To enable age
and gender matching, all groups were matched with the
13 RA patients with active disease, to result in 52 partic-
ipants in total with 13 in each of the three RA groups
and 13 in the healthy control group for statistical
analysis.
Each group consisted of 10 females and 3 males
(Table 1). At the time of the study, the 26 RA patients
with active disease and those in remission were on the
following therapies: prednisolone 5/26 (19.2%), HCQ 5/
26 (19.2%), MTX 16/26 (61.5%), rituximab 4/26 (15.4%),
tofacitinib 1/26 (3.8%), etanercept 1/26 (3.8%), inflixi-
mab 1/26 (3.8%) and adalimumab 2/26 (7.7%). Eleven
of 39 (28%) of the patients were on lipid-lowering ther-
apy (three new RA: one each on simvastatin, atorvasta-
tin and ezetimibe; three active RA: one simvastatin, two
atorvastatin; five remission RA: three simvastatin, two
atorvastatin). Most of the patients were receiving a com-
bination of some of the above therapies. Patients who
were newly diagnosed and healthy controls were on no
treatment. Quantitative MRI and muscle strength for the
healthy controls and RA groups are presented in
Tables 2 and 3. The results of the one-way analysis of
variance demonstrated significant differences between
the four disease groups in T2, fat fraction and muscle
volume, but no significant difference in mean diffusivity
or fractional anisotropy. The CIs around the differences
between the four disease groups excluded 0 and
included clinically meaningful differences [51], providing
preliminary proof-of-concept of differences that would
merit further investigation.
Knee flexion and knee extension correlated with
muscle volume (rs¼0.7, P< 0.001; rs¼0.7, P< 0.001),
and demonstrated a potential weak correlation with T2
(rs¼0.4, P¼ 0.05; rs¼0.4, P¼ 0.04) and fat fraction
(rs¼0.4, P¼ 0.05; rs¼0.4, P¼ 0.04). There was no
evidence for a correlation with mean diffusivity (rs¼0.2,
P¼0.1; rs¼0.1, P¼0.4) and fractional anisotropy
(rs¼0.3, P¼0.05; rs¼0.3, P¼0.05).
Muscle T2
T2 was higher in all RA groups compared with healthy
controls, demonstrating muscle inflammation. Within the
hamstrings, differences between healthy controls vs new
patients, active patients and remission patients were
4.5 ms (95% CI: 2.5, 6.4; P< 0.001), 3 ms (95% CI: 1.1,
4.9; P¼ 0.001) and 5.0 ms (95% CI: 3.0, 6.4; P<0.001),
respectively. Within the quadriceps, differences were
2.6 ms (95% CI: 0.2, 3.7; P¼ 0.02), 3.6 ms (95% CI: 1.9,
5.4; P<0.001) and 1.5 ms (95% CI: 0.3, 3.3; P¼0.1),
respectively (Fig. 1).
Mean diffusivity
For mean diffusivity, CIs around the differences for all
RA groups compared with healthy controls included 0
and did not include clinically meaningful differences.
Within the hamstrings, differences between healthy con-
trols vs new patients, active patients, and remission
patients were 0.02 103 mm2s-1 (95% CI: 0, 0.05;
P¼0.9), 0.04 103 mm2s-1 (95% CI: 0.1, 0.07;
P¼0.4) and 0.03 103 mm2s-1 (95% CI: 0, 0.04;
P¼0.6), respectively. Within the quadriceps, differences
were 0.07103 mm2s-1 (95% CI: 0.16, 0.04; P¼0.3),
0.05 103 mm2s-1 (95% CI: 0.14, 0.06; P¼ 0.6) and
0.04 103 mm2s-1 (95% CI: 0.1, 0.06; P¼0.7),
respectively.









Age (years) 64 (10) 63 (15) 65 (10) 67 (19) 0.2
Weight (kg) 71.4 (35) 78.6 (26) 77.5 (25) 68.3 (26) 0.06
Height (cm) 164.5 (20) 160 (22) 164 (27) 166 (14) 0.2
BMI (kg/m2) 25 (5) 29 (10) 33 (11) 24 (6) 0.03
DAS28 N/A 5.2 (3) 4.8 (3) 1.7 (0.7) <0.001
Patient visual analogue scale (out of 100) N/A 39 (30) 45.8 (25) 12 (12) <0.001
CRP (4 mg/l) N/A 17. (11) 31.5 (59) 12.1 (7) 0.1
ESR (mm/h) N/A 41.1 (31) 16 (29) 10.6 (28) <0.001
Early morning stiffness (min) N/A 63 (58) 71 (289) 2 (13) <0.001
Disease duration (months) N/A N/A 123 (20) 74 (35) 0.001
N/A: not applicable.
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TABLE 2 Quantitative MRI measurements with post hoc Dunnets t test to determine significance























39.3 (38.7, 39.9) 4.7 (2.9, 6.4) 1.34 (1.28, 1.40) 0.39 (0.36, 0.44)
New RA 43.8 (42.2, 45.3) 7.7 (6.3, 9.1) 1.32 (1.27, 1.37) 0.37 (0.34, 0.39)
Active RA 42.3 (41.1, 43.5) 6.8 (6.8, 11.1) 1.30 (1.27, 1.33) 0.40 (0.38, 0.42)
Remission RA 44.3 (43.0, 45.5) 8.9 (7.2, 10.6) 1.31 (1.27, 1.34) 0.34 (0.3, 0.38)




39.1 (38.6, 39.7) 4.4 (3.7, 5.2) 1.36 (1.26, 1.44) 0.33 (0.30, 0.36)
New RA 41.1 (39.6, 42.6) 9.1 (7.2, 11.0) 1.29 (1.27, 1.32) 0.40 (0.36, 0.42)
Active RA 42.8 (41.9, 43.8) 7.3 (6.4, 8.1) 1.31 (1.29, 1.34) 0.35 (0.33, 0.37)
Remission RA 40.6 (39.4, 31.9) 8.9 (7.4, 10.3) 1.32 (1.24, 1.40) 0.39 (0.38, 0.42)
0.02 <0.001 0.5 <0.001



















Healthy control 1453.5 (1258.9, 1648.2) 51.8 (43,3, 60.1) 82.1 (66.1, 98.1) 30.8 (28.9, 32.8)
New RA 936.2 (841.2, 1031.3) 33.4 (25.9, 40.8) 71.1 (52.2, 89.9) 12.8 (11.1, 14.15)
Active RA 1083.0 (984.2, 1181.8) 41.7 (26.6, 56.9) 62.5 (38.5, 86.6) 17.2 (12.5, 21.8)
Remission RA 1141.2 (962.2, 1320.4) 38.5 (26.8, 50.2) 76.4 (55.2, 97.5) 28.9 (23.4, 32.7)
<0.001 0.03 0.5 <0.001
FIG. 1 Quantitative T2 MRI measurements of RA patients
and healthy controls
FIG. 2 Quantitative fat fraction MRI in RA patients and
healthy controls
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Fractional anisotropy
There were no meaningful differences in fractional an-
isotropy between RA patients and healthy controls.
Within the hamstrings, differences between healthy con-
trols vs new patients, active patients and remission
patients were 0.02 (95% CI: 0.08, 0.02; P¼0.4), 0.01
(95% CI: 0.05, 0.06; P¼0.9) and 0.05 (95% CI: 0.1,
0.004; P¼ 0.03), respectively. Within the quadriceps dif-
ferences were 0.07 (95% CI: 0.03, 0.1; P¼0.01), 0.02
(95% CI: 0.02, 0.06; P¼ 0.6) and 0.06 (95% CI: 0.02,
0.1; P¼0.01), respectively.
Muscle fat fraction
Fat fraction was higher in all RA groups compared with
healthy controls, demonstrating fatty infiltration due to
RA. Within the hamstrings, differences between healthy
controls vs new patients, active patients and remission
patients were 3.0% (95% CI: 0.2, 5.8; P¼0.03), 4.2%
(95% CI: 1.6, 6.8; P¼0.002) and 4.2% (95% CI: 1.4,
7.0; P¼0.002), respectively. Within the quadriceps dif-
ferences were 4.6% (95% CI: 2.7, 6.5; P< 0.001), 2.7%
(95% CI: 1.6, 3.9; P<0.001) and 4.9% (95% CI: 2.8,
5.9; P<0.001), respectively (Fig. 2).
Muscle volume
Muscle volume was lower in all RA groups compared
with healthy controls, demonstrating muscle atrophy in
RA. Within the thigh differences between healthy con-
trols vs new patients, active patients and remission
patients were 517.3 cm3 (751, 283; P< 0.001),
370.5 cm3 (95% CI: 605, 136; P¼0.001) and
312.3 cm3 (95% CI: 546. 77; P¼0.006), respective-
ly (Fig. 3).
Muscle strength assessments
Muscle strength was lower in new RA compared with
healthy controls, demonstrating a decrease in strength
due to RA, however CIs for active and remission
patients included 0. Peak flexion (hamstrings) differen-
ces between healthy controls vs new patients, active
patients and remission patients were 18.4 Nm (95% CI:
35, 1; P¼0.03), 10.1 Nm (95% CI: 27, 7; P¼0.3)
and 13.3 Nm (95% CI: 33, 0; P¼ 0.1), respectively.
Peak extension (quadriceps) differences between
healthy controls vs new patients, active patients and re-
mission patients were 11 Nm (95% CI: 45, 22; P¼0.7),
19.6 Nm (95% CI: 52.7, 12.5; P¼0.3) and 5.7 Nm
(95% CI: 40, 28; P¼ 0.9), respectively. Grip strength
differences between healthy controls vs new patients,
active patients and remission patients were 18 kg (95%
CI: 26, 10; P< 0.001), 13.6 kg (95% CI; 22, 05;
P<0.001) and 1.9 kg (95% CI: 10, 5; P¼ 0.8),
respectively.
Discussion
This study suggests that muscle health may be affected
in RA patients from time of diagnosis compared with
age- and gender-matched healthy controls. It provides
preliminary evidence that muscle health may not return
to normal as determined by quantitative MRI and
strength even when patients achieve clinical remission.
We have provided proof-of-concept that there may be
differences in quantitative MRI measurements of the
thigh and muscle strength between RA patients and
healthy controls. These differences were detectable in
new, active and remission disease states. Our results
suggest that muscle changes may occur in the early
stages of RA and persist throughout the disease dur-
ation, even in long-term clinical remission. This means
that current RA treatment may not be influencing the
pathology affecting the muscle and it may be important
to include muscle strengthening interventions in the
treatment pathway for RA. If these preliminary results
are confirmed, then MRI has potential as a diagnostic
guide and management tool in the assessment of
muscles of RA patients.
T2 measurements were raised in RA groups com-
pared with healthy controls, suggesting the identification
of increased oedema in RA patients [52]. It must also be
considered that T2 measurements will be identifying fat
as well as oedema, due to the fat suppression not sup-
pressing olefinic fat, therefore we interpret T2 as muscle
oedema and fatty infiltration.
In this pilot sample, fat fraction was increased in RA
groups compared with healthy controls consistent with
known fatty infiltration in the muscle of RA patients. This
supports previous work using CT scans which deter-
mined that skeletal muscle fat is higher in individuals
with RA compared with healthy controls. They also
found that patients with RA present with similar fatty in-
filtration as older individuals [53]. This suggests that RA
FIG. 3 Quantitative muscle volume MRI measurements
in RA patients and healthy controls
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may mimic a premature aging process within the muscle.
This is important to consider, as muscles that could be per-
ceived as undergoing fat accumulation due to age are in
fact undergoing pathological changes due to the disease.
Muscle volume measurements suggested clinically
significant differences between all the RA groups com-
pared with healthy controls. This agrees with Baker
et al. [54], who showed that RA patients have significant
skeletal muscle mass deficit compared with healthy con-
trols, which results in a decrease in strength. However,
Helliwell and Jackson [55] demonstrated that the reduc-
tion in strength occurs at a faster rate than the loss of
muscle mass, demonstrating the importance of assess-
ing not only muscle mass, but also muscle strength. We
found that muscle strength was lower in all RA groups
compared with healthy controls, even in patients who
had achieved long-term remission, while muscle volume
was lower in all patients, including newly diagnosed
treatment-naı̈ve patients. Our results suggested the dif-
ference was smallest for those in clinical remission, but
this may still be meaningful compared with healthy con-
trols. In addition, for the first time, this study has shown
that muscle volume measured with MRI correlates with
muscle strength in RA patients. This suggests that
muscle volume is a patient-relevant assessment tool.
Mean diffusivity did not show clinically significant differ-
ences in RA patients compared with healthy controls.
Given that T2 was higher in RA, one might expect to
see raised mean diffusivity due to increased fluid.
However, the increased fatty infiltration seen could also
restrict diffusion. Our results suggest that diffusion
measurements should be used with caution in the study
of RA as the competing influence of fat and oedema
can reduce the overall sensitivity of the measurement.
Our results were consistent with reduced fractional an-
isotropy in the quadriceps in RA patients. This could
have been due to the atrophy of type II muscle fibres,
which are found in greater quantity in the quadriceps
compared with the hamstrings [56], caused by the de-
nervation of motor units, which has been demonstrated
to occur in RA patients [57].
Handgrip strength and knee extension and flexion
were lower in RA groups compared with healthy con-
trols. This could be due to a sedentary lifestyle, joint de-
formity, pain and stiffness, which are factors associated
with muscle deconditioning, muscle wasting and subse-
quent weakness in RA.
Although the patients in clinical remission had better
clinical outcomes, their muscle strength and quantitative
MRI were not markedly better. This suggests that al-
though treatment is effective in improving disease activ-
ity (DAS28) and increasing physical function, even those
with well controlled disease who are in clinical remission
are still significantly weaker than age- and gender-
matched healthy controls. Therefore, future RA therapies
could trial strategies such as the use of exercise inter-
ventions to improve the muscle health of RA patients.
As the diffusion measurements in skeletal muscle did
not appear to be altered in RA, future quantitative MRI
research should focus on T2, fat fraction and muscle
volume measurements in RA patients, as the develop-
ment of muscle-related interventions for RA patients is
an important aspect.
Our study is subject to some limitations. The patients
with active drug-resistant RA had a longer disease dur-
ation than the patients in clinical remission, which may
increase the likelihood of the effect of the disease and
medication on the muscles assessed by quantitative
MRI measurements; however, there was no correlation
between any quantitative MRI parameters and disease
duration (T2: rs¼0.04, P¼ 0.7; fat fraction: rs¼0.01,
P¼0.09; mean diffusivity: rs¼ 0.09, P¼ 0.5; fractional
anisotropy; rs¼0.1, P¼0.1; muscle volume: rs¼0.1,
P¼0.4). The 2-point Dixon imaging technique did not
correct for T2* effects, eddy currents, noise-related bias
or the spectral complexity of fat. However, multiple
studies have failed to show that the errors inherent to 2-
point Dixon confound fat measurements in muscle in ei-
ther ex vivo or in vivo analysis [39, 40, 42]. Furthermore,
2-point Dixon correlates strongly with confounder-
corrected fat quantitation methods and with spectros-
copy [39, 40]. The sample size, despite conforming to
guidelines in powering future studies, was small. Our
muscle volume estimates were taken over a constant
leg length, at a set distance above the patella, and took
no account of different heights or femur lengths be-
tween patients. Differences in shape and length of thigh
muscles between patients will introduce variation in the
muscle volume estimates that our study has not
accounted towards. We attempted to control for these
differences by positioning relative to an anatomical ref-
erence marker, with the distal end of both coils posi-
tioned 4 cm from the superior edge of the patella.
This study did not account for BMI, dyslipidaemia or
physical activity levels of participants. This may have
affected results, as it would be expected that overweight
individuals, or those with high cholesterol, may have a
lower muscle quality compared with individuals of a
healthy weight or those who partake in regular physical
activity. Of note is, while remission patients showed no dif-
ference in BMI compared with healthy controls, the MRI
measurements could still detect differences. The duration
of prednisolone treatment could additionally cause
glucocorticoid-induced myopathy [58], but this study did
not control for the duration of prednisolone therapy. Future
research should consider controlling for duration of any
glucocorticoid therapy, cholesterol, BMI and physical ac-
tivity levels, such as measuring International Physical
Activity Questionnaire scores [59].
In conclusion, this study provides evidence that
muscle damage occurs in patients with RA, irrespective
of disease phenotype, and that quantitative MRI is sen-
sitive enough to identify these differences. These
muscle changes are apparent even in early RA and
muscles do not recover, even in sustained clinical re-
mission, suggesting that RA induces long-term muscle
damage. This muscle deterioration is measurable by
MRI T2, fat fraction, muscle volume and muscle
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strength. There is evidence that physical activity and ex-
ercise helps maintain health and has a role in RA dis-
ease management [60]. Therefore, these quantitative
MRI measures could be useful in monitoring muscle
change in RA and assessing exercise interventions.
Following on from the results of this preliminary study,
future research should investigate how quantitative MRI
can be used to further understand muscle changes in
RA in relation to developing exercise interventions to re-
store muscle quality.
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